WASHINGTON, D.C. (May 12, 2017) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement:
“We had a productive meeting with Health and Human Services Secretary Tom Price in which we expressed our commitment to working with the Administration to advance market-based reforms, such as addressing barriers to value-based payment arrangements, enhancing generic competition and ensuring patients benefit from the discounts and rebates negotiated by payers.
“We share the Administration’s goal of ensuring patients have access to life-changing therapies and look forward to continuing a dialogue on market-based solutions that will enhance competition and address patient affordability challenges.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.